Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504643 | 0.92 | NR1H4 (0.40) | SMPD1MEN1KMT2ANR1H4HRH3 | |
| SCHEMBL4506386 | 0.83 | KMT2A (0.43) | SMPD1MEN1KMT2ANR1H4TP53 | |
| SCHEMBL4496429 | 0.81 | KMT2A (0.44) | MEN1KMT2ANR1H4TP53NPC1 | |
| SCHEMBL4508885 | 0.81 | ALDH1A1 (0.40) | MEN1KMT2ATP53NPC1HTT | |
| SCHEMBL1932569 | 0.81 | KMT2A (0.46) | MEN1KMT2ATP53NPC1HTT | |
| SCHEMBL13918698 | 0.81 | ALDH1A1 (0.39) | MEN1KMT2ATP53NPC1RAB9A | |
| SCHEMBL4502430 | 0.80 | NR1H4 (0.42) | SMPD1KMT2ANR1H4 | |
| SCHEMBL13918694 | 0.79 | ALDH1A1 (0.38) | MEN1KMT2ASMN1; SMN2HSD17B10 | |
| SCHEMBL4507260 | 0.77 | MAPT (0.38) | MEN1KMT2ATP53NPC1RAB9A | |
| SCHEMBL4503884 | 0.77 | DAPK3 (0.47) | MEN1KMT2ANPC1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9120819-B2 | FGF-receptor agonist dimeric compounds | SANOFI (FR) | 2015-09-01 | — | — | US | disclosed |
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | SANOFI-AVENTIS (FR) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069368-A1 | FGF-RECEPTOR AGONIST DIMERIC COMPOUNDS | FGF2, FGFR1, FGF1 | SMPD1 2013/4885MEN1 621/4885KMT2A 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.